LB Pharmaceuticals reports Q4 net loss $11.5M; cash $295.2M; advances LB-102 into Phase 3

LB PHARMACEUTICALS INC

Positive Phase 2 (NOVA-1) results for LB-102 in acute schizophrenia met primary endpoint; Phase 3 NOVA-2 initiated March 2026 with data expected H2 2027.
Phase 2 ILLUMINATE-1 trial in bipolar depression started Jan 2026; Phase 2 for adjunctive MDD planned early 2027.
September 2025 IPO raised $327.8M (21.85M shares at $15); February 2026 private placement added $100M.
Cash and investments $295.2M at Dec 31, 2025; with private placement, runway into Q2 2029.
Q4 2025 net loss $11.5M ($5.1M Q4 2024); full-year net loss $25.2M ($63.1M 2024); R&D expenses declined YoY.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LB PHARMACEUTICALS INC reported financial results for fourth quarter and full year ended December 31, 2025.

Period: fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 26, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2025.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

LB PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-126223

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.